Esperion Therapeutics (ESPR) Non-Current Debt (2012 - 2026)
Esperion Therapeutics (ESPR) posted Non-Current Debt of $152.7 million for Q1 2026, little changed on a QoQ basis from $152.2 million in Q4 2025, and up 7.94% year-over-year from $141.4 million in Q1 2025.
Esperion Therapeutics (ESPR) Non-Current Debt (2012 - 2026) Analysis & Trends
Esperion Therapeutics' Non-Current Debt history runs 8 years deep, the most recent figure standing at $152.7 million for Q1 2026.
- Quarterly Non-Current Debt rose 7.94% year-over-year to $152.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $152.7 million (up 7.94% YoY) and the FY2025 annual result came in at $152.2 million, up 7.98% from the prior year.
- Non-Current Debt was $152.7 million for Q1 2026 at Esperion Therapeutics, roughly flat from $152.2 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $152.7 million in Q1 2026 and bottomed at $141.0 million in Q4 2024.
- A 3-year average of $147.6 million and a median of $149.1 million in 2025 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2025 — Non-Current Debt advanced 7.98% — and 2026, when it climbed 7.94%.
- Esperion Therapeutics' Non-Current Debt stood at $141.0 million in 2024, then grew by 7.98% to $152.2 million in 2025, then grew by 0.3% to $152.7 million in 2026.
- Business Quant data shows ESPR's Non-Current Debt at $152.7 million in Q1 2026, $152.2 million in Q4 2025, and $151.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 152.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 152.67 Mn |
| Dec 31, 2025 | 152.22 Mn |
| Sep 30, 2025 | 151.65 Mn |
| Jun 30, 2025 | 146.45 Mn |
| Mar 31, 2025 | 141.45 Mn |
| Dec 31, 2024 | 140.97 Mn |
| Jun 30, 2017 | 140,000.00 |
| Mar 31, 2017 | 585,000.00 |
| Dec 31, 2016 | 1.02 Mn |
| Sep 30, 2016 | 1.45 Mn |
| Jun 30, 2016 | 1.87 Mn |
| Mar 31, 2016 | 2.28 Mn |
| Dec 31, 2015 | 2.69 Mn |
| Sep 30, 2015 | 3.08 Mn |
| Jun 30, 2015 | 3.47 Mn |
| Mar 31, 2015 | 3.86 Mn |
| Dec 31, 2014 | 4.23 Mn |
| Sep 30, 2014 | 4.68 Mn |
| Jun 30, 2014 | 5.00 Mn |
| Dec 31, 2012 | 7.53 Mn |